Tonix Pharmaceuticals Holding Corp. (TNXP) Raised to Buy at Roth Capital

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) was upgraded by research analysts at Roth Capital from a “neutral” rating to a “buy” rating in a research report issued to clients and investors on Friday.

Separately, Aegis began coverage on shares of Tonix Pharmaceuticals Holding Corp. in a research report on Monday, June 26th. They issued a “buy” rating and a $10.00 price target on the stock.

Tonix Pharmaceuticals Holding Corp. (TNXP) opened at 2.97 on Friday. Tonix Pharmaceuticals Holding Corp. has a 1-year low of $2.91 and a 1-year high of $28.00. The company’s market capitalization is $22.30 million. The firm’s 50-day moving average is $3.90 and its 200-day moving average is $3.27.

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) last released its quarterly earnings results on Monday, August 14th. The company reported ($0.65) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.78) by $0.13. Equities research analysts predict that Tonix Pharmaceuticals Holding Corp. will post ($3.16) EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Tonix Pharmaceuticals Holding Corp. (TNXP) Raised to Buy at Roth Capital” was originally published by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The original version of this story can be read at https://www.com-unik.info/2017/08/18/tonix-pharmaceuticals-holding-corp-tnxp-raised-to-buy-at-roth-capital.html.

In related news, CEO Seth Lederman acquired 20,000 shares of the stock in a transaction dated Tuesday, June 20th. The shares were acquired at an average price of $4.22 per share, for a total transaction of $84,400.00. Following the completion of the purchase, the chief executive officer now owns 7,912 shares in the company, valued at approximately $33,388.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ernest Mario sold 6,105 shares of the firm’s stock in a transaction on Friday, June 30th. The stock was sold at an average price of $4.28, for a total transaction of $26,129.40. Following the completion of the sale, the director now owns 63,073 shares in the company, valued at approximately $269,952.44. The disclosure for this sale can be found here. In the last 90 days, insiders bought 30,000 shares of company stock worth $128,050. 4.00% of the stock is currently owned by corporate insiders.

Several large investors have recently made changes to their positions in TNXP. Citadel Advisors LLC bought a new stake in shares of Tonix Pharmaceuticals Holding Corp. during the first quarter valued at about $119,000. Dialectic Capital Management LP bought a new stake in shares of Tonix Pharmaceuticals Holding Corp. during the first quarter valued at about $187,000. Vanguard Group Inc. increased its stake in shares of Tonix Pharmaceuticals Holding Corp. by 28.8% in the second quarter. Vanguard Group Inc. now owns 184,377 shares of the company’s stock valued at $799,000 after buying an additional 41,264 shares during the last quarter. B. Riley Financial Inc. bought a new stake in shares of Tonix Pharmaceuticals Holding Corp. during the second quarter valued at about $1,637,000. Finally, Renaissance Technologies LLC increased its stake in shares of Tonix Pharmaceuticals Holding Corp. by 108.4% in the fourth quarter. Renaissance Technologies LLC now owns 774,603 shares of the company’s stock valued at $364,000 after buying an additional 402,898 shares during the last quarter. Institutional investors and hedge funds own 17.50% of the company’s stock.

Tonix Pharmaceuticals Holding Corp. Company Profile

Tonix Pharmaceuticals Holding Corp., a clinical-stage pharmaceutical company, engages in developing pharmaceutical products for central nervous system disorders. The company’s lead program focuses on post-traumatic stress disorder (PTSD) that is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden.

What are top analysts saying about Tonix Pharmaceuticals Holding Corp.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Tonix Pharmaceuticals Holding Corp. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit